Cypherpunk Technologies, Inc. (CYPH)
2.55
+0.19
(+8.05%)
USD |
NASDAQ |
Nov 03, 14:20
Cypherpunk Technologies Enterprise Value : 246.74M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 246.74M |
| October 30, 2026 | 313.55M |
| October 29, 2026 | 349.11M |
| October 28, 2026 | 341.57M |
| October 27, 2026 | 330.26M |
| October 26, 2026 | 297.39M |
| October 23, 2026 | 296.31M |
| October 22, 2026 | 313.55M |
| October 21, 2026 | 351.27M |
| October 20, 2026 | 295.23M |
| October 19, 2026 | 265.06M |
| October 16, 2026 | 269.37M |
| October 15, 2026 | 317.86M |
| October 14, 2026 | 274.76M |
| October 13, 2026 | 298.46M |
| October 12, 2026 | 304.93M |
| October 09, 2026 | 309.24M |
| October 08, 2026 | 295.23M |
| October 07, 2026 | 321.10M |
| October 06, 2026 | 343.73M |
| October 05, 2026 | 334.03M |
| October 02, 2026 | 318.94M |
| October 01, 2026 | 307.09M |
| September 30, 2026 | 351.27M |
| September 29, 2026 | 340.49M |
| Date | Value |
|---|---|
| September 28, 2026 | 349.11M |
| September 25, 2026 | 436.40M |
| September 24, 2026 | 432.09M |
| September 23, 2026 | 381.44M |
| September 22, 2026 | 394.38M |
| September 21, 2026 | 358.81M |
| September 18, 2026 | 380.37M |
| September 17, 2026 | 323.25M |
| September 16, 2026 | 255.36M |
| September 15, 2026 | 231.65M |
| September 14, 2026 | 270.45M |
| September 11, 2026 | 236.50M |
| September 10, 2026 | 229.50M |
| September 09, 2026 | 256.44M |
| September 08, 2026 | 275.83M |
| September 04, 2026 | 253.20M |
| September 03, 2026 | 237.04M |
| September 02, 2026 | 173.46M |
| September 01, 2026 | 176.69M |
| August 31, 2026 | 189.08M |
| August 28, 2026 | 176.69M |
| August 27, 2026 | 196.09M |
| August 26, 2026 | 168.07M |
| August 25, 2026 | 169.15M |
| August 24, 2026 | 173.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Indaptus Therapeutics, Inc. | 454.79M |
| Cue Biopharma, Inc. | 92.97M |
| Yarrow Bioscience, Inc. | -10.94M |
| Faeth Therapeutics, Inc. | 317.69M |
| Pyxis Oncology, Inc. | 90.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 39.39M |
| Total Expenses (Quarterly) | -39.39M |
| EPS Diluted (Quarterly) | 0.1812 |
| Earnings Yield | 22.18% |
| Normalized Earnings Yield | -2.733 |